![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted pr... Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Show more
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with...
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to...
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.68 | 3.19849482596 | 21.26 | 23.32 | 20.5561 | 683400 | 21.60712079 | CS |
4 | 1.11 | 5.32885261642 | 20.83 | 24.3773 | 18.65 | 991301 | 21.40055401 | CS |
12 | 8.79 | 66.8441064639 | 13.15 | 24.3773 | 12.7 | 1032069 | 18.37138491 | CS |
26 | 13.75 | 167.887667888 | 8.19 | 24.3773 | 7.65 | 1021916 | 15.59272617 | CS |
52 | 12.43 | 130.704521556 | 9.51 | 24.3773 | 4.22 | 794306 | 12.78618792 | CS |
156 | -8.58 | -28.1127129751 | 30.52 | 37.425 | 4.22 | 530269 | 14.57609966 | CS |
260 | 1.69 | 8.34567901235 | 20.25 | 52.38 | 4.22 | 481614 | 17.66396625 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions